In the claims:

Please amend claims 1, 2, 4-8 and 10 as follows:

1. (Amended) A method for treating or preventing gastritis in a subject, somprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

2. (Amended) A method for treating or preventing gastric ulceration in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin is not a calcitonin or a CGRP.

4. (Amended) [A method of enhancing the analgesic activity of a non-steroidal anti-inflammatory drug in a subject,] The method of claim 1 or 2, further comprising administering [an amylin agonist along with said] a non-steroidal anti-inflammatory drug[, wherein said amylin agonist is not a calcitonin].

(Amended) The method according to any of claims 1-2 [1-4], wherein said subject is human.

(Amended) The method of according to any of claims <u>1-2</u> [1-4], wherein said amylin or amylin agonist is administered by a route selected from the group consisting of nasal, oral, pulmonary, transdermal, and buccal administration.

(Amended) The method according to any of claims [1-4] <u>1-2</u> wherein said amylin agonist is selected from the group consisting of ¹⁸Arg^{25,28}Pro-h-amylin [SEQ. ID. NO. 4],

SD-114956.2

des-¹Lys¹⁸Arg^{25,28}Pro-h-amylin [SEQ. ID. NO. 5], ¹⁸Arg^{25-28,29}Pro-h-amylin [SEQ. ID. NO. 7], des-¹Lys¹⁸Arg^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 8], ^{25,28-29}Pro-h-amylin [SEQ. ID. NO. 1], des-¹Lys^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 9], ²⁵Pro²⁶Val^{28,29}Pro-h-amylin [SEQ. ID. NO. 6], ²³Leu²⁵Pro²⁶Val^{28,29}Pro-h-amylin [SEQ. ID. NO. 10], ²³Leu²⁵Pro²⁶Val²⁸Pro-h-amylin [SEO. ID. NO. 11], des-\(^1\text{Lys}^2\)\(^3\text{Leu}^2\)\(^2\)\(^2\)\(^2\)\(^2\)\(^2\)\(^3\)\(^2\)\(^2\)\(^2\)\(^3\)\(^2\)\(^2\)\(^3\)\(^2\)\(^3\)\(^2\)\(^3\)\(^3\)\(^2\)\(^3\ amylin [SEQ. ID. NO. 13], ¹⁸Arg²³Leu^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 14], ¹⁸Arg²³Leu^{25,28}Proh-amylin [SEQ. ID. NO. 15], ¹⁷Ile²³Leu^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 16]</sup>, ¹⁷Ile^{25,28,29}Pro-hamylin [SEQ. ID. NO. 17], des-1Lys17Ile23Leu25,28,29Pro-h-amylin [SEQ. ID. NO. 18], Tile¹⁸Arg²³Leu-h-amylin [SEQ. ID. NO. 19], ¹⁷Ile¹⁸Arg²³Leu²⁶Val²⁹Pro-h-amylin [SEQ. ID. NO. 20], ¹⁷Ile¹⁸Arg²³Leu²⁵Pro²⁶Val^{28,29}Pro-h-amylin [SEQ. ID. NO. 21], ¹³Thr²¹His²³Leu²⁶Ala²⁸Leu²⁹Pro³¹Asp-h-amylin [SEQ. ID. NO. 22], ¹³Thr²¹His²³Leu²⁶Ala²⁹Pro³¹Asp-h-amylin [SEQ. ID. NO. 23], des-¹Lys¹³Thr²¹His²³Leu²⁶Ala²⁸Pro³¹Asp-h-amylin [SEQ. ID. NO. 24], ¹³Thr¹⁸Arg²¹His²³Leu²⁶Ala²⁹Pro³¹Asp-h-amylin [SEQ. ID. NO. 25], ¹³Thr¹⁸Arg²¹His²³Leu^{28,29}Pro³¹Asp-h-amylin [SEQ. ID. NO. 26], and ¹³Thr¹⁸Arg²¹His²³Leu²⁵Pro²⁶Ala^{28,29}Pro³¹Asp-h-amylin [SEQ. ID. NO. 27].

8. (Amended) The method according to any of claims 1-2 [1-4], wherein said amylin agonist is 25,28,29 Pro-h-amylin [SEQ. ID. NO. 1].